DE69203443T2 - Verwendung von interleukin-10 in der adoptive immunotherapie von krebs. - Google Patents

Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.

Info

Publication number
DE69203443T2
DE69203443T2 DE69203443T DE69203443T DE69203443T2 DE 69203443 T2 DE69203443 T2 DE 69203443T2 DE 69203443 T DE69203443 T DE 69203443T DE 69203443 T DE69203443 T DE 69203443T DE 69203443 T2 DE69203443 T2 DE 69203443T2
Authority
DE
Germany
Prior art keywords
interleukin
tils
cancer
adoptive immunotherapy
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69203443T
Other languages
English (en)
Other versions
DE69203443D1 (de
Inventor
Di-Hwei Hsu
Kevin Moore
Hergen Spits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE69203443D1 publication Critical patent/DE69203443D1/de
Application granted granted Critical
Publication of DE69203443T2 publication Critical patent/DE69203443T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69203443T 1991-01-16 1992-01-15 Verwendung von interleukin-10 in der adoptive immunotherapie von krebs. Expired - Fee Related DE69203443T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64134291A 1991-01-16 1991-01-16
PCT/US1992/000067 WO1992012726A1 (en) 1991-01-16 1992-01-15 Use of interleukin-10 in adoptive immunotherapy of cancer

Publications (2)

Publication Number Publication Date
DE69203443D1 DE69203443D1 (de) 1995-08-17
DE69203443T2 true DE69203443T2 (de) 1995-12-07

Family

ID=24571960

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69203443T Expired - Fee Related DE69203443T2 (de) 1991-01-16 1992-01-15 Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.

Country Status (17)

Country Link
US (1) US5776451A (de)
EP (2) EP0567586B1 (de)
JP (1) JPH06505250A (de)
CN (1) CN1063308A (de)
AT (1) ATE124866T1 (de)
AU (1) AU1273992A (de)
DE (1) DE69203443T2 (de)
DK (1) DK0567586T3 (de)
ES (1) ES2074879T3 (de)
GR (1) GR3017597T3 (de)
IE (1) IE68836B1 (de)
IL (1) IL100667A0 (de)
MX (1) MX9200161A (de)
MY (1) MY108267A (de)
NZ (1) NZ241321A (de)
WO (1) WO1992012726A1 (de)
ZA (1) ZA92304B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
AU707019B2 (en) * 1994-01-20 1999-07-01 Schering Corporation Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
WO1997031532A1 (en) * 1996-02-28 1997-09-04 University Of Medicine & Dentistry Of New Jersey Antisense interleukin 10 and methods of use
JP2001500369A (ja) 1996-08-30 2001-01-16 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド インターロイキン―１９
AU6517900A (en) * 1999-08-03 2001-02-19 Smith & Nephew, Inc. Controlled release implantable devices
EP1349873B1 (de) 2000-09-14 2009-04-01 Beth Israel Deaconess Medical Center, Inc. Modulierung von il-2 und il-15 vermittelten t zellantworten
EP1324779B1 (de) 2000-09-29 2011-07-20 Schering Corporation Pegyliertes interleukin 10
JP2006522022A (ja) 2003-02-14 2006-09-28 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ プロテアソーム干渉に関連する避妊法および組成物
US7294262B2 (en) * 2003-08-27 2007-11-13 Sta-Rite Industries, Llc Modular fluid treatment apparatus
CA2664304C (en) 2006-09-28 2017-08-22 Schering Corporation Use of pegylated il-10 to treat cancer
US20080089875A1 (en) * 2006-10-13 2008-04-17 Zheng Cui Methods and compositions for the treatment of cancer
EP2374813A1 (de) 2008-12-03 2011-10-12 Proyecto de Biomedicina Cima, S.L. Verwendung von phenollöslichen modulinen zur entwicklung von impfstoffen
PL2379115T3 (pl) 2008-12-17 2018-03-30 Merck Sharp & Dohme Corp. Wytwarzanie i zastosowania mono- i di-peg il-10
CA2750922A1 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-key hybrid peptides that modulate the immune response to influenza
SG10201407936XA (en) * 2009-11-30 2015-01-29 Biotest Ag Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (de) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
EP2986306A4 (de) 2013-04-18 2016-12-07 Armo Biosciences Inc Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
JP6509867B2 (ja) 2013-08-30 2019-05-08 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためにインターロイキン−１０を使用する方法
KR20160083884A (ko) 2013-11-01 2016-07-12 스페리움 바이오메드 에스.엘. 치료제 및 미용제의 경피 전달을 위한 봉입체
ES2862139T3 (es) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
JP6728061B2 (ja) 2014-05-05 2020-07-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
JP2017536098A (ja) 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
KR20170084033A (ko) 2014-10-22 2017-07-19 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
MX2017016134A (es) 2015-06-11 2018-08-15 Lycera Corp Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
US20200368293A1 (en) * 2018-01-18 2020-11-26 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer
TW202120521A (zh) 2019-08-16 2021-06-01 美商應用分子運輸公司 組合物、配方及介白素生產及純化
CN110669139A (zh) * 2019-09-18 2020-01-10 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
CN114805538B (zh) * 2022-05-20 2023-06-09 广州智瓴生物医药有限公司 一种增强til功效的培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
WO1990004633A1 (en) * 1988-10-21 1990-05-03 Brigham And Women's Hospital ACTIVATION AND GROWTH OF HUMAN TUMOR-INFILTRATING LYMPHOCYTES USING ANTIBODIES TO CD3 OR TcR
DE69012105T2 (de) * 1989-02-21 1994-12-22 Terumo Corp Proliferation von cd4-lymfocyten.
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same

Also Published As

Publication number Publication date
GR3017597T3 (en) 1996-01-31
US5776451A (en) 1998-07-07
IE68836B1 (en) 1996-07-10
EP0567586A1 (de) 1993-11-03
MY108267A (en) 1996-09-30
ATE124866T1 (de) 1995-07-15
WO1992012726A1 (en) 1992-08-06
EP0567586B1 (de) 1995-07-12
MX9200161A (es) 1992-07-01
DK0567586T3 (da) 1995-12-04
DE69203443D1 (de) 1995-08-17
IL100667A0 (en) 1992-09-06
ES2074879T3 (es) 1995-09-16
JPH06505250A (ja) 1994-06-16
ZA92304B (en) 1992-09-30
AU1273992A (en) 1992-08-27
EP0495639A1 (de) 1992-07-22
NZ241321A (en) 1997-06-24
CN1063308A (zh) 1992-08-05
IE920113A1 (en) 1992-07-29

Similar Documents

Publication Publication Date Title
ATE124866T1 (de) Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.
Niederwieser et al. IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses.
Rook et al. The immunopathogenesis of cutaneous T-cell lymphoma: abnormal cytokine production by Sézary T cells
ATE20073T1 (de) Homogenes human-interleukin-2 und verfahren zu seiner herstellung.
EP0668781A4 (de) Lymphokine gentherapie bei krebs.
DE69032086D1 (de) Zytotoxischer Lymphozyten-Reifefaktor
EP0211769A3 (en) Adoptive immunotherapy as a treatment modality in humans
ZA967756B (en) Adoptive immunitherapy using macrophages sensitized with heat shock protein-epitope complexes
DK226288A (da) Fremgangsmaade til fremstilling af lak-celler in vitro
DK0789588T3 (da) Metode til fremstilling af et medikament til behandling af sekundær immundefekt
DE3678736D1 (de) Labdanderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel.
ATE167519T1 (de) T-zellen-wachstumsfaktor
Flynn et al. Production of interleukin-1 and interleukin-2 in allogeneic mixed lymphocyte cultures under copper, magnesium and zinc deficient conditions
EP0094317A3 (de) Herstellung von Interleukin und dessen analogen immunregulierenden Faktoren
DE3683956D1 (de) In einem serumfreien medium in suspension kultivierte humane monozyten.
YU4792A (sh) Postupak gajenja tumornih infiltirajućih limfocita
Hansson Growth and differentiation factors for B and T cells
JPS57115180A (en) Preparation of human tyroid-stimulating hormone
GR3018004T3 (en) Process to prepare metastasis-inhibitory factor.
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2
GB8817082D0 (en) Method for production of lymphokine activated killer(lak)cells so produced & their use
GB8729410D0 (en) Method for production of lymphokine activated killer(lak)cells & lak cells so produced

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee